GlobeNewsWire
10 Nov 2025, 13:55 UTC · 45w ago
Verdict
Headline takes no side. We score AIM +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
A Phase 2 trial of Ampligen combined with cisplatin and pembrolizumab in advanced recurrent ovarian cancer showed an Objective Response Rate (ORR) of 50%.
So whatA 50% ORR is a significant clinical improvement over the referenced pembrolizumab-only ORRs of 7.4% and 9.9%, suggesting high efficacy for the lead product.
More positive than 99% of claims this week
AIM ImmunoTech holds synergistic patents for Ampligen in combination with checkpoint inhibitors in the U.S., Japan, and the Netherlands, expiring in 2039.
So whatLong-term intellectual property protection provides a durable competitive moat and commercial runway for the drug's potential market entry.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 87% of claims this week
The study indicates Ampligen may act as a synergistic agent for patients who are refractory to checkpoint inhibitors alone.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported positive Phase 2 clinical trial results showing a 50% objective response rate for Ampligen in ovarian cancer.
More positive than 55% of ticker scores this week
The article highlights the efficacy of its drug Keytruda when used in combination with Ampligen, though it also references some non-responders in monotherapy studies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
8h ago
−88.0%
Price is moving against the score
$0.1901 vs $1.58 close before publication (Nov 7) · not market-adjusted
AIM chart →
